Orthofix International ( (OFIX) ) has released its Q4 earnings. Here is a breakdown of the information Orthofix International presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthofix Medical Inc., headquartered in Lewisville, Texas, is a global medical technology company specializing in spinal hardware, bone growth therapies, and orthopedic solutions. The company offers a comprehensive portfolio that includes the 7D FLASH™ navigation system, catering to musculoskeletal pathologies worldwide.
Orthofix has reported its financial results for the fourth quarter and full-year 2024, highlighting record net sales and strategic growth in key areas. The company achieved an 8% increase in fourth-quarter net sales, amounting to $215.7 million, and a 7% increase for the full year, totaling $799.5 million. Despite a net loss, the company demonstrated strong execution in its spine, orthopedics, and bone growth therapies sectors.
Key financial metrics include a 12% growth in U.S. Spine Fixation net sales and a 9% increase in Bone Growth Therapies net sales for the fourth quarter. The Global Orthopedics segment also saw significant growth, with a constant currency increase of 18%. Orthofix reported a non-GAAP adjusted EBITDA of $23.9 million for the fourth quarter, reflecting a 22% growth compared to the previous year. The company also improved its free cash flow to $15.2 million in the fourth quarter.
Strategically, Orthofix has decided to discontinue its M6-C and M6-L artificial disc product lines to focus on more profitable growth opportunities in spinal fixation and deformity correction. This decision aligns with the company’s increased long-term net sales CAGR target of 6.5% to 7.5%.
Looking ahead, Orthofix projects net sales for 2025 to range between $818 million and $826 million, with non-GAAP adjusted EBITDA expected to be between $82 million and $86 million. The company remains focused on leveraging its unique portfolio to drive profitable growth and value creation in the coming years.